Rezolute reports Q3 FY2024 net loss $17.1M; sunRIZE Phase 3 enrolling, DME Phase 2 topline expected May 2024

Rezolute, Inc.

2024-Q3 EPS reported -$0.89

Net loss $17.1M for Q3 FY2024 vs $15.7M YoY; cash and equivalents $81.6M (down from $118.4M in June 2023).
sunRIZE Phase 3 for cHI (RZ358) enrolling; completion expected end-2024; topline data mid-2025.
Completed in-vivo tox study in brown Norway rats at 40 mg/kg; no liver abnormalities; to submit to FDA summer 2024.
DME Phase 2 (RZ402) completed dosing of 94 patients; topline results expected May 2024.
FDA alignment for potential registrational study in tumor HI; 5 insulinoma patients treated under Expanded Access.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rezolute, Inc. reported the three months ended March 31, 2024 results: net income $17.1 million.

Period: the three months ended March 31, 2024
Net income: $17.1 million
Result: reported results

Exact text from the filing

Net loss was $17.1 million for the third quarter of fiscal 2024 compared with a net loss of $15.7 million for the same period a year ago.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-061933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.